Describe in detail how the subjects of the Study may file co

Describe in detail how the subjects of the Study may file complaints during the implementation of the Program (testing the blood samples of the function of mir-22 in cancer)

Solution

A research participant, also called a human subject or an experiment, trial, or study participant or subject, is a person who participates in human subject research by being the target of observation by researchers.

That means some drug will experiment on human it is called as subject , healthy subject,or ill subject or canser releted subject , in of them researcher are give dose of some small amout of drug for testing of drugs on them so if it takes or by mistake give them some extra dose in sort time of period it may be affect so it is depend on good clinical practise and following sop means srandard opereting procedure and you must follow sop means researcher must follow it them take sample of subject and them sample analysis of subject sample in bioanalytical lab where analyst work there

               Implementation is the carrying out, execution, or practice of a plan, a method, or any design, idea, model, specification, standard or policy for doing something. As such, implementation is the action that must follow any preliminary thinking in order for something to actually happen.

Mir-22

Mir-22 was originally identified in HeLa cells (an immortal cell line derived from cervical cancer cells), but was later found to be ubiquitously expressed in various tissues. The gene encoding miR-22 is found on the short arm of chromosome 17, in a minimal loss of heterozygosity region. It is highly conserved across many vertebrate species, including chimp, mouse, rat, dog and horse. This level of conservation suggests functional importance. MiR-22 was previously identified as having a role in erythrocyte maturation.

The deregulation of many miRNAs has been shown to have a role in oncogenesis. Mir-22 was found to be over-expressed in prostate cancer but down-regulated in breast cancer, cholangiocarcinoma, multiple myeloma and hepatocellular carcinoma

Specifically, miR-22 can function as a tumour suppressor. One known target is histone deacetylase 4 (HDAC4), which is known to have a critical role in cancer development. Mir-22 also targets Myc Binding Protein (MYCBP). This prevents transcription of c-Myc target genes by silencing c-MYCBP. However, c-Myc also inhibits expression of miR-22 in a positive feedback loop. When this spirals out of control, it can cause uncontrolled cell proliferation.

Expression of miR-22 can be induced by adding 12-O-Tetradecanoylphorbol-13-acetate (TPA) to HL-60 cells (leukaemia cell line). The enforced expression causes the growth of cancer cells to slow down. This means that miR-22 could be a potential target for cancer therapies.